Hui Xiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hui Xiang has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Dating Sun
Department of Cardiology, Wuhan NO.1 Hospital
1 shared publicationQi-Ping Liu
Department of Pulmonary and Critical Care Medicine, Chongqing University Three Gorges Hospital, Chongqing 404100, China
1 shared publicationXin Liu
Infectious Disease Department, Chongqing University Three Gorges Hospital
1 shared publicationYonghong Chen
Infectious Disease Department, Chongqing University Three Gorges Hospital
1 shared publication- Zhi-Gang She
State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases, Gannan Innovation and Translational Medicine Research Institute; School of Pharmacy; First Affiliated Hospital, Gannan Medical University, Ganzhou, China
1 shared publication
Latest Publications
- Open Access
- 21 December 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (47) , 6689-6701
Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential
Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential
- 21 December 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 28 (47) , 6689-6701
Open AccessAlterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential
Alterations of the gut microbiota in coronavirus disease 2019 and its therapeutic potential
- Open Access
- 8 February 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 812610
The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious disease threatening public health, and its pathogenesis remains largely unclear. Recent scientific research has shown that intestinal microbiota and its metabolites have an important impact on the development of NASH. A balanced intestinal microbiota contributes to the maintenance of liver homeostasis, but when the intestinal microbiota is disequilibrated, it serves as a source of pathogens and molecules that lead to NASH. In this review, we mainly emphasize the key mechanisms by which the intestinal microbiota and its metabolites affect NASH. In addition, recent clinical trials and animal studies on the treatment of NASH by regulating the intestinal microbiota through prebiotics, probiotics, synbiotics and FMT have also been briefly elaborated. With the increasing understanding of interactions between the intestinal microbiota and liver, accurate and personalized detection and treatment methods for NASH are expected to be established.
- 8 February 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 812610
Open AccessThe Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis
Nonalcoholic steatohepatitis (NASH) is a serious disease threatening public health, and its pathogenesis remains largely unclear. Recent scientific research has shown that intestinal microbiota and its metabolites have an important impact on the development of NASH. A balanced intestinal microbiota contributes to the maintenance of liver homeostasis, but when the intestinal microbiota is disequilibrated, it serves as a source of pathogens and molecules that lead to NASH. In this review, we mainly emphasize the key mechanisms by which the intestinal microbiota and its metabolites affect NASH. In addition, recent clinical trials and animal studies on the treatment of NASH by regulating the intestinal microbiota through prebiotics, probiotics, synbiotics and FMT have also been briefly elaborated. With the increasing understanding of interactions between the intestinal microbiota and liver, accurate and personalized detection and treatment methods for NASH are expected to be established.